



**World Health  
Organization**

## **CORRIGENDA Rev. 1<sup>1</sup>**

### **19th WHO Model List of Essential Medicines (April 2015)<sup>2</sup>**

#### **Page 13, lines 21–22**

*Delete:* **efavirenz + emtricitabine + tenofovir:** **Tablet:** 600 mg + 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil).

*Insert:* **efavirenz + emtricitabine\* + tenofovir:** **Tablet:** 600 mg + 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil).

\* Emtricitabine (FTC) is an acceptable alternative to 3TC, based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals.

#### **Page 13, lines 23–24**

*Delete:* **emtricitabine + tenofovir:** **Tablet:** 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil).

---

<sup>1</sup> Please note that the corrections listed here apply to the electronic version of the document found here: [http://www.who.int/medicines/news/eml\\_2015/en/](http://www.who.int/medicines/news/eml_2015/en/). The revised version of the 19th Model List, incorporating these corrections can be found here: <http://www.who.int/medicines/publications/essentialmedicines/en/>

<sup>2</sup> The 19th WHO Model List of Essential Medicines will be published in the report of the WHO Expert Committee on the Selection and Use of Essential Medicines. (The selection and use of essential medicines. Report of the WHO Expert Committee, 2015 (including the 19th WHO Model List of Essential Medicines and 5th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; in press: Annex 1 (WHO Technical Report Series, No. 994).

*Insert:* **emtricitabine\* + tenofovir:**

**Tablet:** 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil).

\* Emtricitabine (FTC) is an acceptable alternative to 3TC, based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals.

**Page 14, line 24**

*Delete:* **daclatasvir:**

**Tablet:** 30 mg (as hydrochloride).

*Insert:* **daclatasvir:**

**Tablet:** 30 mg, 60 mg (as hydrochloride).

**Page 20, lines 35–37**

*Delete:* **daunorubicin:**

**Powder for injection:** 50 mg (hydrochloride) in vial.  
– acute myelogenous leukemia  
– acute promyelocytic leukemia

*Insert:* **daunorubicin:**

**Powder for injection:** 50 mg (hydrochloride) in vial.  
– acute lymphoblastic leukemia  
– acute myelogenous leukemia  
– acute promyelocytic leukemia

**Page 23, lines 29–31**

*Delete:* **trastuzumab:**

**Dose form:**  
– early stage HER2 positive breast cancer  
– metastatic HER2 positive breast cancer.

*Insert:* **trastuzumab:**

**Powder for injection:** 60 mg,  
150 mg, 440 mg in vial.

- *early stage HER2 positive breast cancer*
- *metastatic HER2 positive breast cancer.*

**Page 32, line 11**

*Delete:*        **18.3.5 Intravaginal contraceptives**

*Insert:*        **18.3.6 Intravaginal contraceptives**

**Page 35, line 23**

*Delete:* **[DATE]**

*Insert:* 27 February 2015

**Page 44, line 11**

*Delete:* ~~emtricitabine~~        ~~≥3 months~~